WO1996006627A1 - Mutant enterotoxin effective as a non-toxic oral adjuvant - Google Patents

Mutant enterotoxin effective as a non-toxic oral adjuvant Download PDF

Info

Publication number
WO1996006627A1
WO1996006627A1 PCT/US1995/009005 US9509005W WO9606627A1 WO 1996006627 A1 WO1996006627 A1 WO 1996006627A1 US 9509005 W US9509005 W US 9509005W WO 9606627 A1 WO9606627 A1 WO 9606627A1
Authority
WO
WIPO (PCT)
Prior art keywords
vaccine
spp
antigen
composition
subunit
Prior art date
Application number
PCT/US1995/009005
Other languages
English (en)
French (fr)
Inventor
John D. Clements
Bonny L. Dickinson
Original Assignee
The Administrators Of The Tulane Educational Fund
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA2198586A priority Critical patent/CA2198586C/en
Priority to HU9801472A priority patent/HU222985B1/hu
Priority to EP95928662A priority patent/EP0777490B1/en
Priority to PL95318930A priority patent/PL182667B1/pl
Priority to DE69534992T priority patent/DE69534992T2/de
Priority to JP50873596A priority patent/JP3860208B2/ja
Priority to NZ291262A priority patent/NZ291262A/xx
Priority to AU32337/95A priority patent/AU709779B2/en
Application filed by The Administrators Of The Tulane Educational Fund filed Critical The Administrators Of The Tulane Educational Fund
Priority to BR9508633A priority patent/BR9508633A/pt
Priority to CZ0056297A priority patent/CZ298131B6/cs
Publication of WO1996006627A1 publication Critical patent/WO1996006627A1/en
Priority to MXPA/A/1997/001445A priority patent/MXPA97001445A/xx
Priority to FI970799A priority patent/FI120137B/fi
Priority to NO19970993A priority patent/NO317942B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Definitions

  • the present invention is directed towards a genetically distinct mutant of E. coli heat-labile enterotoxin (LT) and its use as an oral adjuvant to induce mucosal and serum antibodies.
  • LT heat-labile enterotoxin
  • the mutant LT is modified by a single amino acid substitution that abolishes its inherent toxicity but leaves intact the adjuvant properties of the molecule.
  • Microbial pathogens can infect a host by one of several mechanisms. They may enter through a break in the integument induced by trauma, they may be introduced by vector transmission, or they may interact with a mucosal surface. The majority of human pathogens initiate disease by the last mechanism, i.e., following interaction with mucosal surfaces. Bacterial and viral pathogens that act through this mechanism first make contact with the mucosal surface where they may attach and then colonize, or be taken up by specialized absorptive cells (M cells) in the epithelium that overlay Peyer's patches and other lymphoid follicles [Bockman and Cooper, 1973, Am. J. Anat.
  • M cells absorptive cells
  • Organisms that enter the lymphoid tissues may be readily killed within the lymphoid follicles, thereby provoking a potentially protective immunological response as antigens are delivered to immune cells within the follicles (e.g., Vibrio cholerae) .
  • pathogenic organisms capable of surviving local defense mechanisms may spread from the follicles and subsequently cause local or systemic disease (i.e., Salmonella spp. , poliovirus, rotavirus in immunocompromised hosts) .
  • Secretory IgA antibodies directed against specific virulence determinants of infecting organisms play an important role in overall mucosal immunity [Cebra et al., 1986, In: Vaccines 86, Brown et al. (ed.), Cold Spring Harbor Laboratory, New York. p.p. 129-133]. In many cases, it is possible to prevent the initial infection of mucosal surfaces by stimulating production of mucosal slgA levels directed against relevant virulence determinants of an infecting organism. Secretory IgA may prevent the initial interaction of the pathogen with the mucosal surface by blocking attachment and/or colonization, neutralizing surface acting toxins, or preventing invasion of the host cells.
  • parenteral vaccines are not effective at eliciting mucosal slgA responses and are ineffective against bacteria that interact with mucosal surfaces and do not invade (e.g., Vibrio cholerae..
  • parenterally administered vaccines may be effective against at least one virus, rotavirus, that interacts primarily with mucosal surfaces [Conner et al., 1993, J. Virol. 67:6633-6641]. Protection is presumed to result from transudation of antigen specific IgG onto mucosal surfaces for virus neutralization. Therefore, mechanisms that stimulate both serum and mucosal antibodies are important for effective vaccines.
  • Oral immunization can be effective for induction of specific slgA responses if the antigens are presented to the T and B lymphocytes and accessory cells contained within the Peyer's patches where preferential IgA B-cell development is initiated.
  • the Peyer's patches contain helper T (TH)-cells that mediate B-cell isotype switching directly from IgM cells to IgA B-cells.
  • the patches also contain T-cells that initiate terminal B-cell differentiation.
  • the primed B-cells then migrate to the mesenteric lymph nodes and undergo 5 differentiation, enter the thoracic duct, then the general circulation, and subsequently seed all of the secretory tissues of the body, including the lamina intestinal of the gut and respiratory tract. IgA is then produced by the mature plasma cells, complexed with membrane-bound Secretory
  • PDL poly-DL-lactide-glycolide
  • PDL protein-like polymers - proteinoids
  • gelatin capsules different formulations of liposomes [Alving et al., 1986, Vaccine 4:166-172; Garcon and Six, 1993, J. Immunol.
  • CT cholera toxin
  • LT heat-labile enterotoxin
  • the extensive diarrhea of cholera is the result of a potent exo-enterotoxin which causes the activation of adenylate cyclase and a subsequent increase in intracellular levels of cyclic 3-,5-adenosine onophosphate (cAMP) .
  • the cholera enterotoxin (CT) is an 84,000 dalton polymeric protei composed of two major, non-covalently associated, immunologically distinct regions or domains ("cholera-A" and H cholera-B”) [Finkelstein and LoSpalluto, 1969, J. Exp. Med. 130: 185-202].
  • the 56,000 dalton region or choleragenoid
  • G M1 galactosyl-N-acetylgalactosaminyl- (sialyl)- galactosyl-glucosyl ceramide
  • Choleragenoid is composed of five non-covalently associated subunits, while the A region (27,000 daltons) is responsible for the diverse biological effects of the toxin.
  • CT is an excellent immunogen that provokes the development of both serum and mucosal antitoxin antibody responses when delivered orally. This finding is not new in that cholera patients are known to develop rises in titers of antitoxin antibodies during convalescence from clinical cholera [Finkelstein, 1975, Curr. Top. Microbiol. Immunol. 69: 137-196].
  • CT unlike most other protein antigens, does not induce oral tolerance against itself [Elson and Ealding, 1984, J. Immunol.
  • CT has a number of other reported immunologic properties. As indicated above, Elson and Ealding [Elson and Ealding, 1984, J. Immunol. 133: 2892-2897] observed that orally administered CT does not induce tolerance against itself. Moreover, simultaneous oral administration of CT with a soluble protein antigen, keyhole limpet he ocyanin (KLH) , resulted in the development of secretory IgA responses against both CT and KLH and also abrogated the induction of oral tolerance against KLH. These findings were subsequently confirmed and extended by Lycke and Holmgren [Lycke and Holmgren, 1986, Immunology 59:301-308].
  • KLH keyhole limpet he ocyanin
  • CT can prevent the induction of tolerance against other antigens with which it is simultaneously delivered and also serve as an adjuvant for those antigens [Elson and Ealding, 1984, J. Immunol. 133: 2892-2897; Lycke and Holmgren, 1986, Immunology 59:301-308].
  • CT can act as and adjuvant for CT-B [Elson and Ealding, 1984, J. Immunol. 133: 2892-2897].
  • CT-B can serve as an immunologic "carrier" in a traditional hapten-carrier configuration [Cebra et al., 1986, In: Vaccines 86, Brown et al. (ed.). Cold Spring Harbor
  • Lycke and Holmgren [Lycke and Holmgren, 1986, Immunology 59:301-308] compared CT and CT-B for the ability to enhance the gut mucosal immune response to KLH by measuring immunoglobulin secreting cells in the lamina limbal hyperplasia.
  • Liang et al. [Liang et al., 1988, J. Immunol. 141: 1495-1501] found no adjuvant effect when CT-B was administered orally in conjunction with inactivated Sendai virus.
  • B-subunit can serve as an immunologic vehicle for presentation of antigens to the immune system. If those antigens are sufficiently small as to be poorly immunogenic, they can be made immunogenic in a traditional hapten-carrier configuration.
  • antigens are sufficiently small as to be poorly immunogenic, they can be made immunogenic in a traditional hapten-carrier configuration.
  • any potential advantage to this mechanism of antigen stabilization may be offset by the distribution of the antigen across non-immunologically relevant tissues, i.e., the surface of intestinal epithelial cells.
  • the immunologically relevant sites are the Peyer's patches, especially for antigen-specific T cell-dependent B cell activation [Strober and Jacobs, 1985, In: Advances in host defense mechanisms. Vol. 4. Mucosal
  • Antigens localized on the epithelial cell surface may contribute to antigen induced B cell proliferation in that the class II positive villous epithelial cells may act as antigen presenting cells for T cell activation at the secretory site, thereby increasing cytokine production, terminal B cell differentiation, increased expression of secretory component, and increased external transport of antigen specific IgA [To asi, T. B., and A.G. Plaut. 1985, In: Advances in host defense mechanisms. Vol. 4. Mucosal Immunity, Gallin and Fauci (ed.), Raven Press, New York. p.p. 31-61]. The relationships of these events have not been clearly defined for B-subunit as a carrier of other antigens and use of the term "adjuvant" would seem inappropriate for such an effect.
  • the adjuvant property of the molecule resides in the holotoxin in which B-subunit is required for receptor recognition and to facilitate penetration of the A-subunit into the cell.
  • the A-subunit is also required for adjuvant activity, presumably as a function of its ADP-ribosylating enzymatic activity and ability to increase intracellular levels of cAMP (see below) .
  • the B-subunit alone may act as a carrier of other antigens in that when conjugate to those antigens they can be immobilized for processing by the gut associated lymphoid tissues.
  • LT and CT have many features in common, these are clearly distinct molecules with biochemical and immunologic differences which make them unique, including a 20% difference in nucleotide and amino acid sequence homology [Dallas and Falkow, 1980, Nature 288: 499-501].
  • the two toxins have the same subunit number and arrangement, same biological mechanism of action, and the same specific activity in many in vitro assays [Clements and Finkelstein, 1979, Infect. Immun. 24:760-769; Clements et al., 1980, Infect. Immun. 24: 91-97].
  • LT remains cell associated and is only released from E. coli during cell lysis [Clements and Finkelstein, 1979, Infect. Immun. 24:760-769].
  • CT is secreted from the vibrio as soon as it is synthesized and can be readily identified in, and purified from, culture supernatants. Consequently, in contrast to CT, LT is not fully biologically active when first isolated from the cell. Consistent with the A-B model for bacterial toxins, LT requires proteolysis and disulfide reduction to be fully active.
  • the enzymatically active A, moiety is unable to dissociate from the A 2 component and cannot reach its target substrate (adenylate cyclase) on the basolateral surface of the intestinal epithelial cell.
  • target substrate adenylate cyclase
  • proteases in the culture supernatant, to which the toxin is exposed during purification perform the proteolysis. Since LT is not fully biologically active, it is difficult to identify during purification using in vitro biological assays such as the Y-l adrenal cell assay or permeability factor assay.
  • LT has an unusual affinity for carbohydrate containing matrices. Specifically, LT, with a molecular weight of 90,000, elutes from Sephadex columns (glucose) with an apparent molecular weight of 45,000 and from Agarose columns (galactose) with an apparent molecular weight of 0. That is, it binds to galactose containing matrices and can be eluted from those matrices in pure form by application of galactose. LT binds not only to agarose in columns used for purification, but more importantly, to other biological molecules containing galactose, including glycoproteins and lipopolysaccharides.
  • This lectin-like binding property of LT results in a broader receptor distribution on mammalian cells for LT than for CT 5 which binds only to G M1 . This may account in part for the reported differences in the abilities of these two molecules to induce different helper T lymphocyte responses [McGhee et al., 1994, Mucosal Immunology Update, Spring 1994, Raven Press, New York. p. 21].
  • mice with vaccines such as tetanus toxoid (TT) with CT as a mucosal adjuvant selectively induces T H 2 type cells in Peyer's
  • the present inventors examined a number of parameters, including the effect of LT on oral tolerance to OVA and the role of the two subunits of LT in the observed response, the effect of varying the timing and route of delivery of LT, the effect of prior exposure to OVA on the ability of LT to influence tolerance to OVA, the use of LT as an adjuvant with two unrelated antigens, and the effect of route of immunization on anti-OVA responses.
  • the results obtained from these studies [Clements et al., 1988, Vaccine 6:269-277; Clements et al., 1988, Abstract No. B91, 88th Ann. Meet. Am. Soc. Microbiol.] are summarized below:
  • Tamura et al. Studies by Tamura et al., [Tamura et al., U.S. Patent No. 5,182,109] demonstrated that LT and/or CT administered intranasally enhanced the antibody titer against a co- administered antigen. However, nowhere in Tamura et al. is it taught that these toxins can induce a protective immune response when administered orally.
  • LT has significant immunoregulatory potential, both as a means of preventing the induction of tolerance to specific antigens and as an adjuvant for orally administered antigens and it elicits the production of both serum IgG and mucosal IgA against antigens with which it is delivered.
  • this "toxin" can stimulate a net lumenal secretory response when proteolytically cleaved, as by gut proteases, or when administered in high enough concentrations orally, may hinder investigation into its potential or prevent its use under appropriate conditions.
  • both LT and CT are synthesized as multisubunit toxins with A and B components. After the initial interaction of the toxin with the host cell membrane receptor, the B region facilitates the penetration of the A-subunit through the cell membrane. On thiol reduction, this A component dissociates into two smaller polypeptide chains.
  • the A, piece catalyzes the ADP-ribosylation of the stimulatory GTP-binding protein (G s ) in the adenylate cyclase enzyme complex on the basolateral surface of the epithelial cell and this results in increasing intracellular levels of cAMP.
  • G s stimulatory GTP-binding protein
  • the resulting increase in cAMP causes secretion of water and electrolytes into the small intestine through interaction with two cAMP-sensitive ion transport mechanisms involving 1) NaCl co-transport across the brush border of villous epithelial cells, and 2) electrogenic Na + dependent Cl " secretion by crypt cells [Field, 1980, In: Secretory diarrhea. Field et al.
  • the A subunit is also the principal moiety associated with immune enhancement by these toxins. This subunit then becomes a likely target for manipulation in order to dissociate the toxic and immunologic functions of the molecules.
  • Lycke et al. [Lycke et al., 1992, Eur. J. Immunol. 22:2277-2281] makes it clear that alterations that affect the ADP-ribosylating enzymatic activity of the toxin and alter the ability to increase intracellular levels of cAMP also prevent the molecule from functioning as an adjuvant. Consequently, another approach to detoxification must be explored.
  • the present invention is based on the surprising observation that a mutant form of LT, which has lost its toxic effect and is devoid of ADP-ribosyltransferase activity, still retains its activity as an immunological adjuvant.
  • the mutant form of LT differs from the wild-type by a single amino acid substitution, Arg ⁇ -Gly ⁇ , rendering a trypsin sensitive site insensitive. The loss of the proteolytic site prevents the proteolytic processing of the A subunit into its toxic form.
  • Native LT is not toxic when first isolated from the bacterium but has the potential to be fully toxic when exposed to proteases such as those found in the mammalian intestine.
  • mLT This mutant LT
  • This mutant LT retains the capability of enhancing an animal's immune response (e.g., IgG, IgA) to an antigen unrelated to LT or mL with no toxic side effects.
  • IgG an animal's immune response
  • IgA an antigen unrelated to LT or mL
  • Experimental evidence shows that mLT has utility as an adjuvant for orally administered antigens; such administration results in the production of serum IgG and/or mucosal slgA against the antigen with which the mLT is delivered.
  • the present invention provides a method for induction of a serum and/or mucosal immune response in a host to any orally administered antigen which comprises administering to the host an effective amount of mLT in conjunction with oral administration of an effective amount o the antigen.
  • the antigen and the mLT are administered initially in a simultaneous dose.
  • the present method and compositions provide an improved mode of oral immunization for development of serum and mucosal antibodies against pathogenic microorganisms.
  • Production of IgA antibody responses against pathogenic microorganisms which penetrate or invade across mucosal surfaces can be directed to that surface, while a significant serum antibody response can be developed to prevent infection by pathogenic microorganisms against which serum antibody is protective.
  • the present invention is useful for any specific antigen where a specific neutralizing antibody response would be useful in ablating the physiological or disease state associated with that antigen.
  • the present invention also provides a composition useful as a component of a vaccine against enterotoxic bacterial organisms expressing cholera-like enterotoxins and methods for its use.
  • the invention also provides a composition useful in these methods.
  • the composition comprises an effective amount of mLT in combination with an effective amount of antigen. 4.
  • Figure l Schematic diagram of the plasmid pBD94, which encodes both subunits A and B under the control of the lac promoter.
  • Plasmid pBD95 contains the single base substitution at amino acid residue 192 of subunit A, coding for Gly rather than Arg, which preserves the reading frame but eliminates the proteolytic site.
  • the amino acid sequence corresponding to the region of trypsin sensitivity and the site of the amino acid substitution Arg ⁇ -Gly, ⁇ is shown.
  • Figure 2 Graphic demonstration of the dose-dependent increase in the levels of ADP-ribosylagmatine as a function of increasing amounts of CT.
  • Figure 3 Fluid accumulation after feeding 125 ⁇ g of native LT but not after feeding 125 ⁇ g of mLT to mice.
  • the gut-carcass ratio is defined as the intestinal weight divided by the remaining carcass weight.
  • Figure 4. Ability of mLT to act as an immunological adjuvant.
  • Figure 4A Ability of mLT to induce a serum IgG response to OVA.
  • Figure 4B Ability of mLT to induce a mucosal slgA response to OVA.
  • Figure 5 Experimental demonstration that mLT retains the ability to prevent induction of oral tolerance to LT.
  • Figure 5A Ability of mLT to induce a serum IgG response to LT.
  • Figure 5B Ability of mLT to induce a mucosal slgA response to LT.
  • the present invention encompasses a composition and methods for its use to promote the production of mucosal and serum antibodies against antigens that are simultaneously orally administered with a genetically modified bacterial toxin.
  • the modified toxin is a form of the heat-labile enterotoxin (LT) of £. coli which through genetic engineering has lost its trypsin sensitive site rendering the molecule non-toxic but yet, unexpectedly, retains its ability to act a an immunological adjuvant.
  • the mutant LT is herein termed "mLT”.
  • the invention is based on the discovery that mLT is as effective as LT as an immunological adjuvant, an unexpected and surprising result.
  • mLT no longer has the enzymatic activity of ADP-ribosylation because the A subunit can no longer be proteolytically processed.
  • the presently described mLT retains activity as an immunological adjuvant although, as demonstrated in the examples, it does not have ADP-ribosylating activity.
  • the novel mutant form of the heat-labile enterotoxin of £. coli. mLT behaves as an adjuvant and elicits the production of both serum IgG and mucosal slgA against antigens with which it is delivered.
  • an adjuvant effective amoun of mLT may be utilized in an effective immunization program against a variety of pathogens involving the oral administration of an effective amount of mLT adjuvant in admixture with killed or attenuated pathogens or relevant virulence determinants of specific pathogens with no fear of the real or potential toxic side-effects associated with oral administration of CT or LT.
  • the present invention supersedes the prior art in that the present invention may be used in a variety of immunological applications where CT, LT, or subunits of CT or LT may have been used, but now with mLT there are no real or potential side-effects, such as diarrhea, associated with its use.
  • mLT which although not toxic when first isolated from the bacterium, has the potential to be fully toxic when exposed to proteases such as those found in the mammalian intestine, mLT does not have the potential to become toxic due to proteolytic activation.
  • Another embodiment of the present invention is as a component of a vaccine against enterotoxic organisms which express cholera-like toxins.
  • the present inventors have shown that mLT is not subject to orally induced immune tolerance when administered (see below) , therefore mLT can function and is highly desired as a component of vaccines directed against enterotoxic organisms.
  • Current technology provides for vaccines against cholera-like toxin expressing organisms containing killed whole cells and the B subunit of the toxin.
  • the vaccine is improved in two different ways. First, mLT, which has both the A and B subunits will now induce an immune response not only to the B subunit but to the A subunit as well. This provides for more epitopes for effective neutralization. Second, the adjuvant activity inherent in mLT will enhance the immune response against the killed whole cell component of the vaccine.
  • the A subunit modified so that it is no longer toxic by altering the active site of the ADP-ribosylating enzymatic activity, (as opposed to the proteolytic site which is the subject of the current invention) can induce an immune response against the wild type A subunit.
  • the A subunit so modified now lacks immunologic adjuvant activity and is therefore less desirable as a vaccine component than mLT.
  • mLT can be used in vaccines directed against many types of enterotoxic bacterial organisms that express cholera-like toxins, such as Escherichia spp. and Vibrio spp.
  • the wild-type LT toxin is encoded on a naturally occurring plasmid found in strains of enterotoxigenic £. coli capable of producing this toxin.
  • the present inventors had previously cloned the LT gene from a human isolate of £. coli designated H10407.
  • This subclone consists of a 5.2 kb DNA fragment from the enterotoxin plasmid of H10407 inserted into the Pstl site of plasmid pBR322 [ lements et al, 1983, Infect. Immun. 40:653].
  • This recombinant plasmid, designated pDF82 has been extensively characterized and expresses LT under control of the native LT promoter.
  • the next step in this process was to place the LT gene under the control of a strong promoter, in this case the lac promoter on plasmid pUC18. This was accomplished by isolating the genes for LT-A and LT-B separately and recombining them in a cassette in the vector plasmid. This was an important step because it permitted purification of reasonable quantities of LT and derived mutants for subsequent analysis.
  • This plasmid, designated pBD94 is shown diagrammatically in Figure 1.
  • CT and LT are synthesized with a trypsin sensitive peptide bond that joins the A, and A 2 pieces. This peptide bond must be nicked for the molecule to be "toxic". This is also true for diphtheria toxin, the prototypic A-B toxin, and for a variety of other bacterial toxins. If the A,-A 2 bond is not removed, either by bacterial proteases or intestinal proteases in the lumen of the bowel, the A, piece cannot reach its target on the basolateral surface of the intestinal epithelial cell. In contrast to CT, LT is not fully biologically active when first isolated from the cell. LT also requires proteolysis to be fully active and the proteolytic activation does not occur inside of the bacterium.
  • one means of altering the toxicity of the molecule without affecting the ADP-ribosylating enzymatic activity would be to remove by genetic manipulation the trypsin sensitive amino acids that join the A, and A 2 components of the A subunit. If the molecule cannot be proteolytically cleaved, it will not be toxic. One skilled in the art would predict that the molecule should, however, retain its ADP-ribosylating enzymatic activity and consequently, its adjuvant function.
  • Figure 1 shows the sequence of the disulfide subtended region that separates the A, and A 2 pieces. Within this region is a single Arginine residue which is believed to be the site of cleavage necessary to activate the toxic properties of the molecule. This region was changed by site-directed mutagenesis in such a way as to render the molecule insensitive to proteolytic digestion and, consequently, nontoxic.
  • Site-directed mutagenesis is accomplished by hybridizing to single stranded DNA a synthetic oligonucleotide which is complementary to the single stranded template except for a region of mismatch near then center. It is this region that contains the desired nucleotide change or changes.
  • the oligonucleotide is extended with DNA polymerase to create a double stranded structure.
  • the nick is then sealed with DNA ligase and the duplex structure is transformed into an £. coli host.
  • the theoretical yield of mutants using this procedure is 50% due to the semi-conservative mode of DNA replication. In practice, the yield is much lower.
  • the system employed utilized a second mutagenic oligonucleotide to create altered restriction sites in a double mutation strategy.
  • mLT was then purified by agarose affinity chromatography from one mutant (pBD95) which had been confirmed by sequencing. Alternate methods of purification will be apparent to those skilled in the art.
  • This mutant LT designated LT( R192G ) was then examined by SDS-polyacrylamide gel electrophoresis for modification of the trypsin sensitive bond. Samples were examined with and without exposure to trypsin and compared with native (unmodified) LT. mLT does not dissociate into A !
  • mLT can be administered in conjunction with any biologically relevant antigen and/or vaccine, such that an increased immune response to said antigen and/or vaccine is achieved.
  • the mLT and antigen are administered simultaneously in a pharmaceutical composition comprising an effective amount of mLT and an effective amount of antigen.
  • the mode of administration is oral.
  • the respective amounts of mLT and antigen will vary depending upon the identity of the antigen employed and the species of animal to be immunized.
  • the initial administration of mLT and antigen is followed by a boost of the relevant antigen.
  • no boost is given.
  • the timing of boosting may vary, depending on the antigen and the species being treated. The modifications in dosage range and timing of boosting for any given species and antigen are readily determinable by routine experimentation.
  • the boost may be of antigen alone or in combination with mLT.
  • the mode of administration of the boost may either be oral, nasal, or parenteral; however, if mLT is used in the boost, the administration is preferably oral.
  • the methods and compositions of the present invention are intended for use both in immature and mature vertebrates, in particular birds, mammals, and humans.
  • Useful antigens would include antigens from pathogenic strains of bacteria (Streptococcus pyo ⁇ enes. Streptococcus pneumoniae. Neisseria ⁇ onorrheae. Neisseria meninctitidis. Corynebacterium diphtheriae. Clostridium botulinum. Clostridium perfrin ⁇ ens. Qj.Qstrj.dium te_£_tni. Hemophilus influenzae. Klebsiella pneumoniae. KlefrsjeU ozaenae. Klebsiella rhinoscleromotis. Staphylococcus aureus. Vibrio colerae.
  • Leotospira icterohemorrhagiae Mycobacterium tuberculosis. Toxoplasma ⁇ ondii. Pneumocvstis carinii. Francisella tularensis. __ _cel__a abortus. Brucella suis. Brucella melitensis. Mvcoolasma spp. , BicKettsia rovaZgHi/ Rickettsia tsutsucrumushi. Chlamvdia spp.), pathogenic fungi fCoccidioides immitis. Asper ⁇ illus fumi ⁇ atus. Candida albicans.
  • pathogenic viruses examples and not by limitation: Poxviridae, Herpesviridae, Herpes Simplex virus 1, Herpes Simplex virus 2, Adenoviridae, Papovaviridae, Enteroviridae, Picornaviridae, Parvoviridae, Reoviridae, Retroviridae, influenza viruses, parainfluenza viruses, mumps, measles, respiratory syncytial virus, rubella, Arboviridae, Rhabdoviridae, Arenaviridae, Hepatitis A virus, Hepatitis B virus.
  • pathogenic viruses as examples and not by limitation: Poxviridae, Herpesviridae, Herpes Simplex virus 1, Herpes Simplex virus 2, Adenoviridae, Papovaviridae, Enteroviridae, Picornaviridae, Parvoviridae, Reoviridae, Retroviridae, influenza viruses, parainfluenza viruses, mumps, measles
  • Hepatitis C virus Hepatitis E virus, Non- A/Non-B Hepatitis virus, Rhinoviridae, Coronaviridae, Rotoviridae, and Human Immunodeficiency Virus
  • Hepatitis C virus Hepatitis E virus
  • Non- A/Non-B Hepatitis virus Rhinoviridae
  • Coronaviridae Coronaviridae
  • Rotoviridae and Human Immunodeficiency Virus
  • vaccines include, but are not limited to, vaccines.
  • vaccines include, but are not limited to, influenza vaccine, pertussis vaccine, diphtheria and tetanus toxoid combined with pertussis vaccine, hepatitis A vaccine, hepatitis B vaccine, hepatitis C vaccine, hepatitis E vaccine, Japanese encephalitis vaccine, herpes vaccine, measles vaccine, rubella vaccine, mumps vaccine, mixed vaccine of measles, mumps and rubella, papillomavirus vaccine, parvovirus vaccine, respiratory syncytial virus vaccine, Lyme disease vaccine, polio vaccine, malaria vaccine, varicella vaccine, gonorrhea vaccine, HIV vaccine, schistosomiasis vaccine, rota vaccine, mycoplasma vaccine pneumococcal vaccine, meningococcal vaccine and others.
  • Such vaccines can be produced by known common processes.
  • such vaccines comprise either the entire organism or virus grown and isolated by techniques well known to the skilled artisan or comprise relevant antigens of these organisms or viruses which are produced by genetic engineering techniques or chemical synthesis. Their production is illustrated by, but not limited to, as follows:
  • Influenza vaccine a vaccine comprising the whole or part of hemagglutinin, neuraminidase, nucleoprotein and matrix protein which are obtainable by purifying a virus, which is grown in embryonated eggs, with ether and detergent, or by genetic engineering .techniques or chemical synthesis.
  • Pertussis vaccine a vaccine comprising the whole or a part of pertussis toxin, hemagglutinin and K-agglutin which are obtained from avirulent toxin with formalin which is extracted by salting-out or ultracentrifugation from the culture broth or bacterial cells of Bordetella pertussis, or by genetic engineering techniques or chemical synthesis.
  • Diphtheria and tetanus toxoid combined with pertussis vaccine a vaccine mixed with pertussis vaccine, diphtheria and tetanus toxoid.
  • Japanese encephalitis vaccine a vaccine comprising the whole or part of an antigenic protein which is obtained by culturing a virus intracerebrally in mice and purifying the virus particles by centrifugation or ethyl alcohol and inactivating the same, or by genetic engineering techniques or chemical synthesis.
  • Hepatitis B vaccine a vaccine comprising the whole or part of an antigen protein which is obtained by isolating and purifying the HBs antigen by salting-out or ultracentrifugation, obtained from hepatitis carrying blood, or by genetic engineering techniques or by chemical synthesis.
  • Measles vaccine a vaccine comprising the whole or part of a virus grown in a cultured chick embryo cells or embryonated egg, or a protective antigen obtained by genetic engineering or chemical synthesis.
  • Rubella vaccine a vaccine comprising the whole or part of a virus grown in cultured chick embryo cells or embryonated egg, or a protective antigen obtained by genetic engineering techniques or chemical synthesis.
  • Mumps vaccine a vaccine comprising the whole or part of a virus grown in cultured rabbit cells or embryonated egg, or a protective antigen obtained by genetic engineering techniques or chemical synthesis.
  • Mixed vaccine of measles, rubella and mumps a vaccine produced by mixing measles, rubella and mumps vaccines.
  • Rota vaccine a vaccine comprising the whole or part of a virus grown in cultured MA 104 cells or isolated from the patient's feces, or a protective antigen obtained by genetic engineering techniques or chemical synthesis.
  • Mycoplasma vaccine a vaccine comprising the whole or part of mycoplasma cells grown in a liquid culture medium for mycoplasma or a protective antigen obtained by genetic engineering techniques or chemical synthesis.
  • the vaccine preparation compositions of the present invention can be prepared by mixing the above illustrated antigens and/or vaccines with mLT at a desired ratio.
  • the preparation should be conducted strictly aseptically, and each component should also be aseptic. Pyrogens or allergens should naturally be removed as completely as possible.
  • the antigen preparation of the present invention can be used by preparing the antigen per se and the mLT separately.
  • the present invention encompasses a kit comprising an effective amount of antigen and an adjuvant effective amount of mLT.
  • the components of the kit can either first be mixed together and then administered orally or the components can be administered orally separately within a short time of each other.
  • compositions of the present invention can be combined with either a liquid or solid pharmaceutical carrier, and the compositions can be in the form of tablets, capsules, powders, granules, suspensions or solutions.
  • the compositions can also contain suitable preservatives, coloring and flavoring agents, or agents that produce slow release.
  • Potential carriers that can be used in the preparation of the pharmaceutical compositions of this invention include, but are not limited to, gelatin capsules, sugars, cellulose derivations such as sodium carboxymethyl cellulose, gelatin, talc, magnesium stearate, vegetable oil such as peanut oil, etc., glycerin, sorbitol, agar and water. Carriers may also serve as a binder to facilitate tabletting of the compositions for convenient oral administration.
  • the vaccine preparation composition of this invention may be maintained in a stable storage form for ready use by lyophilization or by other means well known to those skilled in the art.
  • the vaccine preparation may be reconstituted as a suspension in buffered saline, milk, or any other physiologically compatible liquid medium.
  • the medium may be made more palatable by the addition of suitable coloring and flavoring agents as desired.
  • the vaccine preparation compositions may be preceded by an oral dosage of an effective amount of a gastric acid neutralizing agent. While many compounds could be used for this purpose, sodium bicarbonate is preferred. Alternatively, the vaccine compositions may be delivered in enteric coated capsules (i.e., capsules that dissolve only after passing through the stomach) . 6. EXAMPLES The following examples are presented for purposes of illustration only and are not intended to limit the scope of the invention in any way. 6.1 CONSTRUCTION OF mLT
  • the wild-type LT toxin is encoded on a naturally occurring plasmid found in strains of enterotoxigenic £. coli capable of producing this toxin.
  • the present inventors had previously cloned the LT gene from a human isolate of £. coli designated H10407.
  • This subclone consists of a 5.2 kb DNA fragment from the enterotoxin plasmid of H10407 inserted into the Pstl site of plasmid pBR322 [Clements et al., 1983, Infect. Immun. 40:653].
  • This recombinant plasmid, designated pDF82 has been extensively characterized and expresses LT under control of the native LT promoter.
  • the next step in this process was to place the LT gene under the control of a strong promoter, in this case the lac promoter on plasmid pUC18. This was accomplished by isolating the genes for LT-A and LT-B separately and recombining them in a cassette in the vector plasmid. This was an important step because it permitted purification of reasonable quantities of LT and derived mutants for subsequent analysis.
  • This plasmid, designated pDF94 is shown diagrammatically in Figure 1.
  • CT and LT are synthesized with a trypsin sensitive peptide bond that joins the A, and A 2 pieces. This peptide bond must be nicked for the molecule to be "toxic". This is also true for diphtheria toxin, the prototypic A-B toxin, and for a variety of other bacterial toxins. If the A,-A 2 bond is not removed, either by bacterial proteases or intestinal proteases in the lumen of the bowel, i.e.. proteolytic processing or activation, the Aj piece cannot reach its target on the basolateral surface of the intestinal epithelial cell. In contrast to CT, LT is not fully biologically active when first isolated from the cell.
  • LT also requires proteolysis to be fully active and the proteolytic activation does not occur inside of the bacterium. Therefore, one means of altering the toxicity of the molecule without affecting the ADP-ribosylating enzymatic activity would be to remove by genetic manipulation the trypsin sensitive amino acids that join the h, and A- > components of the A subunit. If the molecule cannot be proteolytically cleaved, it will not b toxic. One skilled in the art would predict that the molecule should, however, retain its ADP-ribosylating enzymatic activity and consequently, its adjuvant function.
  • Figure 1 shows the sequence of the disulfide subtended region that separates the A- and A pieces. Within this region is a single Arginine residue which is believed to be the site of cleavage necessary to activate the toxic properties of the molecule. This region was changed by site-directed mutagenesi is such a way as to render the molecule insensitive to proteolytic digestion and, consequently, nontoxic. Site-directed mutagenesis is accomplished by hybridizing to single stranded DNA a synthetic oligonucleotid which is complementary to the single stranded template except for a region of mismatch near then center. It is this region that contains the desired nucleotide change or changes.
  • the oligonucleotide is extended with DNA polymerase to create a double stranded structure.
  • the nick is then sealed with DNA ligase and the duplex structure is transformed into an £. coli host.
  • the theoretical yield of mutants using this procedure is 50% due to the semi-conservative mode of DNA replication. In practice, the yield is much lower.
  • the system employed utilized a second mutagenic oligonucleotide to create altered restriction sites in a double mutation strategy.
  • mLT was then purified by agarose affinity chromatography from one mutant (pBD95) which had been confirmed by sequencing.
  • This mutant LT designated LT( RI92G ) was then examined by SDS-polyacrylamide gel electrophoresis for modification of the trypsin sensitive bond. Samples were examined with and without exposure to trypsin and compared with native (unmodified) LT. mLT does not dissociate into Aj and A 2 when incubated with trypsin, thereby indicating that sensitivity to protease has been removed.
  • Table I demonstrates the unexpected finding that mLT retained a basal level of activity in the Y-l adrenal cell assay even though it could not be proteolytically processed.
  • CT and native LT treated with trypsin have the same level of activity (15 pg) on Y-l adrenal cells.
  • mLT (48,000 pg) was >1,000 fold less active than CT or native LT and could not be activated by trypsin.
  • the residual basal activity undoubtedly reflects a different and here-to-fore unknown pathway of adrenal cell activation than that requiring separation of the A, - A 2 linkage.
  • CT produces a dose-dependent increase in the levels of ADP-ribosylagmatine, a function of the ADP-ribosyltransferase activity of this molecule.
  • Table II demonstrates in tabular form the unexpected finding that mLT lacked any detectable ADP-ribosylating enzymatic activity, with or without trypsin activation, even though the enzymatic site had not been altered and there was a demonstratable basal level of activity in the Y-l adrenal cell assay.
  • mLT lacks any detectable ADP-ribosylating enzymatic activity, with or without trypsin activation, even though the enzymatic site has not been altered and the additional finding that there is a basal level of activity in the Y-l adrenal cell assay, it was unclear whether mLT would retain any of its enterotoxic properties.
  • An ideal adjuvant formulation of mLT would retain its ability to act as an immunological adjuvant but would lack the real or potential side-effects, such as diarrhea. associated with the use of LT or CT.
  • Figure 3 demonstrates that mLT does not induce net fluid secretion in the patent mouse model, even at a dose of 125 ⁇ g. This dose is more tha five times the adjuvant effective dose for LT in this model. Importantly, the potential toxicity of native LT can be seen at this level.
  • mLT has no ADP-ribosylating enzymatic activity and onl some undefined basal activity in Y-l adrenal cells, and induces no net fluid secretion in the patent mouse model.
  • adjuvant activity of mLT the following experiment was performed. Three groups of BALB/c mice were immunized. Animals were inoculated intragastrically with a blunt tipped feeding needle (Popper & Sons, Inc., New Hyde Park, New York) .
  • each group was immunized orally as follows: Group A received 0.5 ml of PBS containing 5 mg of OVA, Group B received 0.5 ml of PBS containing 5 mg of OVA and 25 ⁇ g of native LT, and Group C received 0.5 ml of PBS containing 5 mg of OVA and 25 ⁇ g of mLT. Each regimen was administered again on days 7 and 14. On day 21, all animals were boosted i.p. with 1 ⁇ g of OVA in 20% Maalox. One week after the i.p. inoculation animals were sacrificed and assaye for serum IgG and mucosal IgA antibodies directed against OVA and LT by ELISA.
  • Reagents and antisera for the ELISA were obtained from Sigma Chemical Co. Samples for ELISA were serially diluted in phosphate buffered saline (pH 7.2)-0.05% Tween 20 (PBS-TWEEN) .
  • PBS-TWEEN phosphate buffered saline
  • anti-LT determinations microtiter plates were precoated with 1.5 ⁇ g per well of mixed gangliosides (Type III), then with 1 ⁇ g per well of purified LT.
  • Anti-OVA was determined on microtiter plates precoated with 10 ⁇ g per well of OVA. Serum anti-LT and anti-OVA were determined with rabbit antiserum against mouse IgG conjugated to alkaline phosphatase.
  • Mucosal anti-LT and anti-OVA IgA were assayed with goat antiserum against mouse IgA [alpha-chain specific] followed by rabbit antiserum against goat IgG conjugated to alkaline phosphatase. Reactions were stopped with 3N NaOH. Values for IgG and IgA were determined from a standard curve with purified mouse myeloma proteins (MOPC 315, gA(IgA12) ; MOPC 21, gGl: Litton Bionetics, Inc., Charleston, SC) .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Dental Preparations (AREA)
  • Carbon And Carbon Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
PCT/US1995/009005 1994-08-26 1995-07-18 Mutant enterotoxin effective as a non-toxic oral adjuvant WO1996006627A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
NZ291262A NZ291262A (en) 1994-08-26 1995-07-18 E. coli heat-labile enterotoxin derivatives and their use as oral adjuvants
EP95928662A EP0777490B1 (en) 1994-08-26 1995-07-18 Mutant enterotoxin effective as a non-toxic oral adjuvant
PL95318930A PL182667B1 (pl) 1994-08-26 1995-07-18 Mutant nietrwałej termicznie enterotoksyny holotoksyny z E.coli
DE69534992T DE69534992T2 (de) 1994-08-26 1995-07-18 Mutierendes enterotoxin als nichttoxisches orales adjuvans
JP50873596A JP3860208B2 (ja) 1994-08-26 1995-07-18 非毒性口内アジュバントとして有効な突然変異エンテロトキシン
CA2198586A CA2198586C (en) 1994-08-26 1995-07-18 Mutant enterotoxin effective as a non-toxic oral adjuvant
AU32337/95A AU709779B2 (en) 1994-08-26 1995-07-18 Mutant enterotoxin effective as a non-toxic oral adjuvant
HU9801472A HU222985B1 (hu) 1994-08-26 1995-07-18 Nem-toxikus orális adjuvánsként használható mutáns enterotoxin
BR9508633A BR9508633A (pt) 1994-08-26 1995-07-18 Composição preparação de vacina estojo e processos para criar ou sustentar uma resposta imune protetora ou adaptadora a um antígeno em um hospedeiro e para induzir uma resposta imune protetora contra um organismo bacteriano enterotóxico
CZ0056297A CZ298131B6 (cs) 1994-08-26 1995-07-18 Mutantní forma termolabilního bakteriálního enterotoxinu Escherichia coli, prostredek a vakcína s jeho obsahem a pouzití této mutantní formy
MXPA/A/1997/001445A MXPA97001445A (en) 1994-08-26 1997-02-26 Effective mutating enterotoxin as adjuvant oral no tox
FI970799A FI120137B (fi) 1994-08-26 1997-02-26 Mutanttienterotoksiini, joka on tehokas ei-toksisena suun kautta annettavana adjuvanttina
NO19970993A NO317942B1 (no) 1994-08-26 1997-03-04 Mutant varmelabilt E.coli-enterotoksin-holotoksin, samt vaksinepreparat, sammensetning og kitt inneholdende dette.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US296,848 1994-08-26
US08/296,848 US6019982A (en) 1994-08-26 1994-08-26 Mutant enterotoxin effective as a non-toxic oral adjuvant

Publications (1)

Publication Number Publication Date
WO1996006627A1 true WO1996006627A1 (en) 1996-03-07

Family

ID=23143827

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/009005 WO1996006627A1 (en) 1994-08-26 1995-07-18 Mutant enterotoxin effective as a non-toxic oral adjuvant

Country Status (22)

Country Link
US (2) US6019982A (xx)
EP (1) EP0777490B1 (xx)
JP (1) JP3860208B2 (xx)
KR (1) KR100399258B1 (xx)
CN (1) CN1182868C (xx)
AT (1) ATE326231T1 (xx)
AU (1) AU709779B2 (xx)
BR (1) BR9508633A (xx)
CA (1) CA2198586C (xx)
CZ (1) CZ298131B6 (xx)
DE (1) DE69534992T2 (xx)
DK (1) DK0777490T3 (xx)
ES (1) ES2265148T3 (xx)
FI (1) FI120137B (xx)
HU (1) HU222985B1 (xx)
NO (1) NO317942B1 (xx)
NZ (1) NZ291262A (xx)
PL (1) PL182667B1 (xx)
PT (1) PT777490E (xx)
RU (1) RU2160606C2 (xx)
WO (1) WO1996006627A1 (xx)
ZA (1) ZA956412B (xx)

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0725653A1 (en) 1993-10-05 1996-08-14 Celltech Pharmaceuticals Limited Vaccine compositions
WO1998018928A1 (en) * 1996-10-31 1998-05-07 Chiron S.P.A. Immunogenic detoxified mutant e. coli lt-a toxin
WO1998028005A1 (en) * 1996-12-24 1998-07-02 Smithkline Beecham Biologicals S.A. Chlamydia vaccines
WO1999047165A1 (en) * 1998-03-18 1999-09-23 The Administrators Of The Tulane Educational Fund Production of purified mutant enterotoxin for use as an adjuvant
WO1999047167A1 (en) * 1998-03-18 1999-09-23 The Administrators Of The Tulane Educational Fund Double mutant enterotoxin for use as an adjuvant
US6036953A (en) * 1996-11-29 2000-03-14 The General Hospital Corporation Heterologous antigens in live cell V. cholerae strains
WO2000014114A1 (en) * 1998-09-07 2000-03-16 University Of Bristol Peptide fragments of cholera toxin b or enterotoxin b as vaccine adjuvants
WO2000051634A1 (fr) * 1999-03-03 2000-09-08 The Kitasato Institute Preparations de vaccins contenant des acides gras comme composants
WO2001019998A1 (en) * 1999-09-15 2001-03-22 Mogam Biotechnology Research Institute Novel detoxified mutants of escherichia coli heat-labile enterotoxin
WO2002017961A1 (fr) * 2000-08-31 2002-03-07 The Kitasato Institute Preparation d'un vaccin renfermant un acide gras comme compose
US6521745B1 (en) 1998-08-20 2003-02-18 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
US6693087B1 (en) 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
WO2004020585A2 (en) * 2002-08-27 2004-03-11 Dow Agrosciences Llc Use of escherichia coli heat labile toxin as an adjuvant in birds and poultry
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US7070781B2 (en) * 1993-12-22 2006-07-04 Chiron Srl Nontoxic mucosal adjuvant
EP1676586A1 (en) 1999-08-17 2006-07-05 GlaxoSmithKline Biologicals SA Method of separating rotavirus variants and live attenuated rotavirus vaccine
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
EP1741782A2 (en) 2000-05-10 2007-01-10 Sanofi Pasteur Limited Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
EP1792995A2 (en) 2000-05-08 2007-06-06 Sanofi Pasteur Limited Chlamydia secretory locus orf and uses thereof
US7285281B2 (en) 2001-06-07 2007-10-23 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
US7364739B2 (en) 2000-08-25 2008-04-29 National Research Council Of Canada Haemophilus influenzae lipopolysaccharide inner-core oligosaccharide epitopes as vaccines for the prevention of Haemophilus influenzae infections
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
EP1964573A2 (en) 1999-10-22 2008-09-03 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
WO2008143676A1 (en) 2007-05-23 2008-11-27 The Uab Research Foundation Detoxified pneumococcal neuraminidase and uses thereof
US7632513B2 (en) 1995-06-30 2009-12-15 Novartis Vaccines And Diagnostics Srl Immunogenic detoxified mutants of cholera toxin
US7658931B2 (en) 2001-06-07 2010-02-09 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
WO2010071986A1 (en) 2008-12-24 2010-07-01 Sanofi Pasteur Limited Modified steptococcus pneumonia pneumolysin (ply) polypeptides
EP2272532A2 (en) 2003-09-02 2011-01-12 GlaxoSmithKline Biologicals S.A. Rotavirus vaccine
WO2011003920A1 (en) 2009-07-08 2011-01-13 Abbott Biologicals B.V. Adjuvated influenza vaccine and use thereof
EP2322211A1 (en) 2005-02-17 2011-05-18 GlaxoSmithKline Biologicals S.A. Live attenuated rotavirus vaccine for oral administration
WO2012101509A2 (en) 2011-01-28 2012-08-02 Sanofi Pasteur Sa Immunological compositions against hiv
EP2495327A2 (en) 2006-03-03 2012-09-05 Amorfix Life Sciences Ltd. Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
EP2674169A1 (en) 2007-09-11 2013-12-18 University Of Guelph Polysaccharide immunogens from Clostridium difficile
WO2013191225A1 (ja) 2012-06-20 2013-12-27 国立大学法人 東京大学 粘膜免疫賦活化剤及びｈｐｖ感染症治療用経口医薬組成物
WO2014140938A2 (en) 2013-03-14 2014-09-18 Centre Hospitalier Universitaire Vaudois Immunological methods
US8911742B2 (en) 1996-11-14 2014-12-16 The United States Of America As Represented By The Secretary Of The Army Transcutaneous immunization without heterologous adjuvant
WO2017062246A1 (en) 2015-10-05 2017-04-13 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human rota virus g9p[6] strain and use as a vaccine
WO2017079833A1 (en) 2015-11-09 2017-05-18 The University Of British Columbia Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto
WO2018041891A1 (en) 2016-09-01 2018-03-08 Glaxosmithkline Biologicals Sa Compositions
US10751382B2 (en) 2016-11-09 2020-08-25 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
US10759837B2 (en) 2015-11-09 2020-09-01 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
US10772969B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
IT201900007060A1 (it) 2019-05-21 2020-11-21 St Superiore Di Sanita Cellule tumorali ingegnerizzate e loro usi
IT201900012540A1 (it) 2019-07-22 2021-01-22 Humanitas Mirasole Spa Inibitori di CHI3L1 e loro usi

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0967279B1 (en) * 1992-03-02 2008-01-02 Novartis Vaccines and Diagnostics S.r.l. Helicobacter pylori cytotoxin useful for vaccines and diagnostics
US7141244B1 (en) * 1992-03-02 2006-11-28 Chiron Srl Helicobacter pylori proteins useful for vaccines and diagnostics
AU696941B2 (en) * 1994-07-01 1998-09-24 Rican Limited Helicobacter pylori antigenic protein preparation and immunoassays
US6019982A (en) * 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
FR2726472B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Proteine porteuse a effet adjuvant, complexe immunogene la contenant, leur procede de preparation, sequence nucleotidique et vaccin
EP0909323B1 (en) * 1996-01-04 2007-02-28 Novartis Vaccines and Diagnostics, Inc. Helicobacter pylori bacterioferritin
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
CA2297374A1 (en) * 1997-07-21 1999-01-28 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
US7459524B1 (en) * 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
US20040258703A1 (en) * 1997-11-14 2004-12-23 The Government Of The Us, As Represented By The Secretary Of The Army Skin-active adjuvants for transcutaneous immunization
US6589529B1 (en) * 1998-10-30 2003-07-08 Children's Hospital Medical Center Rotavirus subunit vaccine
ES2462532T3 (es) * 1999-10-18 2014-05-23 Novartis Vaccines And Diagnostics, Inc. Composiciones y métodos para estimular una respuesta inmune contra agentes infecciosos
MY128159A (en) * 2000-06-30 2007-01-31 Wyeth Corp Methods and composition for oral vaccination
PT1372708E (pt) * 2001-02-13 2008-09-29 Us Gov Sec Army Vacina para imunização transcutânea
AU2002252378B2 (en) 2001-03-19 2007-10-18 Intercell Usa, Inc. Transcutaneous immunostimulation
JP2005506322A (ja) * 2001-08-31 2005-03-03 カイロン ソチエタ ア レスポンサビリタ リミタータ Ｈｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉワクチン接種
GB0121998D0 (en) * 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
JP2005538954A (ja) * 2002-05-31 2005-12-22 トーマス・ジェファーソン・ユニバーシティ 分子の経上皮輸送用組成物及び方法
AU2003278496A1 (en) * 2002-11-14 2004-06-03 Pfizer Products Inc. Use of rmlt as a marker antigen for vaccines and as a synergistic adjuvant with amphigen
US20060069052A1 (en) * 2003-02-14 2006-03-30 David Hone DNA vaccines that expresses mutant ADP-ribosyItransferase toxins which display reduced, or are devoid of, ADP-ribosyltransferase activity
WO2004073603A2 (en) * 2003-02-14 2004-09-02 Aeras Global Tuberculosis Vaccine Foundation Dna vaccine that expresses mutant adp-ribosyltransferase toxins which display reduced, or are devoid of, adp-ribosyltransferase activity
US8685718B2 (en) * 2003-05-20 2014-04-01 New York University Mucosal immunization to prevent prion infection
WO2005019412A2 (en) 2003-05-20 2005-03-03 New York University Mucosal immunization to prevent prion infection
WO2005079841A2 (en) * 2003-12-09 2005-09-01 Iomai Corporation Gm1 binding deficient exotoxins for use as immunoadjuvants
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
CN100387719C (zh) * 2005-05-09 2008-05-14 中国农业科学院生物技术研究所 编码大肠杆菌热敏毒素基因及其表达载体和用途
US20090068218A1 (en) * 2005-09-09 2009-03-12 Universitat Zurich Antigens for Vaccination Against and Detection of Mycoplasma Suis
WO2007091911A1 (fr) * 2006-02-09 2007-08-16 Institut Problem Pererabotki Uglevodorodov Sibirskogo Otdeleniya Rossiiskoi Akademii Nauk Sorbant, procédé de fabrication et procédé de séchage d'hydrocarbures
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
BRPI0721746B1 (pt) * 2007-07-18 2021-08-31 Development Center For Biotechnology Polipeptídeo isolado, vacina, ácido nucléico isolado, vetor e células transformadas de bactérias e fungos
DE102007037301A1 (de) * 2007-08-07 2009-02-12 BSH Bosch und Siemens Hausgeräte GmbH Hausgeräteanordnung
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
AU2008293504B2 (en) 2007-08-27 2012-04-12 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
DK2535428T3 (en) 2007-10-01 2015-11-23 Longhorn Vaccines & Diagnostics Llc Biological prøvesamlings- and transport system, and methods of using
BRPI0910168A2 (pt) * 2008-07-01 2019-09-24 Univ George Washington "vacina anti-helmíntica multivalente e método de vacinar um indivíduo em necessidade da mesma contra infecção por ancilóstomo e esquistossomose"
US7927586B2 (en) * 2008-07-08 2011-04-19 South Dakota State University Vaccine for porcine post-weaning diarrhea caused by enterotoxigenic Escherichia coli
CN104203272A (zh) 2012-01-26 2014-12-10 长角牛疫苗和诊断有限责任公司 复合抗原序列及疫苗
WO2014044690A1 (en) 2012-09-18 2014-03-27 Valneva Austria Gmbh Improved vaccines
CA2985652C (en) 2015-05-14 2020-03-10 Gerald W. FISHER Rapid methods for the extraction of nucleic acids from biological samples
CN110075290A (zh) * 2018-01-25 2019-08-02 吴夙钦 流感黏膜疫苗组合物及其制备方法与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
IL101715A (en) * 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
IT1253009B (it) * 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US6019982A (en) * 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
US6033673A (en) * 1998-03-18 2000-03-07 The Administrators Of Tulane Educational Fund Double mutant enterotoxin for use as an adjuvant

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
EUR. J. IMMUNOL., Volume 22, issued 1992, N. LYCKE et al., "The Adjuvant Effect of Vibrio Cholerae and Escherichia Coli Heat-Labile Enterotoxins is Linked to Their ADP-Ribosyltransferase Activity", pages 2277-2281. *
INFECTION AND IMMUNITY, Volume 22, No. 3, issued December 1978, J.D. CLEMENTS et al., "Demonstration of Shared and Unique Immunological Determinants in Enterotoxins from Vibrio Cholerae and Escherichia Coli", pages 709-713. *
INFECTION AND IMMUNITY, Volume 24, No. 3, issued June 1979, J.D. CLEMENTS et al., "Isolation and Characterization of Homogeneous Heat-Labile Enterotoxins With High Specific Activity from Escherichia Coli Cultures", pages 760-769. *
INFECTION AND IMMUNITY, Volume 40, issued May 1983, J.D. CLEMENTS et al., "Cloning and Molecular Characterization of the B Subunit of Escherichia Coli Heat-Labile Enterotoxin", pages 653-658. *
INFECTION AND IMMUNITY, Volume 46, No. 2, issued November 1984, J.D. CLEMENTS et al., "Construction of a Potential Live Oral Bivalent Vaccine for Typhoid Fever and Cholera-Escherichia Coli-Related Diarrheas", pages 564-569. *
JOURNAL OF BACTERIOLOGY, Volume 170, No. 5, issued May 1988, K. OKAMOTO et al., "Effect of Substitution of Glycine for Arginine at Position 146 of the A1 Subunit on Biological Activity of Escherichia Coli Heat-Labile Enterotoxin", pages 2208-2211. *
NATURE, Volume 288, issued 04 December 1980, W.S. DALLAS et al., "Amino Acid Sequence Homology Between Cholera Toxin and Escherichia Coli Heat-Labile Toxin", pages 499-501. *
THE JOURNAL OF INFECTIOUS DISEASES, Volume 158, No. 2, issued August 1988, J.D. CLEMENS et al., "Cross-Protection by B Subunit-Whole Cell Cholera Vaccine Against Diarrhea Associated With Heat-Labile Toxin-Producing Enterotoxigenic Escherichia Coli: Results of a Large-Scale Field Trial", pages 372-377. *
VACCINE, Volume 6, issued June 1988, J.D. CLEMENTS et al., "Adjuvant Activity of Escherichia Coli Heat-Labile Enterotoxin and Effect on the Induction of Oral Tolerance in Mice to Unrelated Protein Antigens", pages 269-277. *

Cited By (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7872114B2 (en) 1991-12-31 2011-01-18 Novartis Vaccines And Diagnostics Srl Immunogenic detoxified mutants of cholera toxin
US7169399B2 (en) 1993-10-05 2007-01-30 Ucb Pharma Limited Non-toxic double mutant forms of pertussis toxin as adjuvants
EP0725653A1 (en) 1993-10-05 1996-08-14 Celltech Pharmaceuticals Limited Vaccine compositions
US7070781B2 (en) * 1993-12-22 2006-07-04 Chiron Srl Nontoxic mucosal adjuvant
US7485304B2 (en) 1993-12-22 2009-02-03 Novartis Vaccines And Diagnostics Srl Non-toxic mucosal adjuvant
US7632513B2 (en) 1995-06-30 2009-12-15 Novartis Vaccines And Diagnostics Srl Immunogenic detoxified mutants of cholera toxin
WO1998018928A1 (en) * 1996-10-31 1998-05-07 Chiron S.P.A. Immunogenic detoxified mutant e. coli lt-a toxin
EP1571214A3 (en) * 1996-10-31 2006-03-29 Chiron S.r.l. Immunogenic detoxified mutant toxin
EP1571214A2 (en) * 1996-10-31 2005-09-07 Chiron S.r.l. Immunogenic detoxified mutant toxin
US7291588B2 (en) 1996-10-31 2007-11-06 Chiron Srl Immunogenic detoxified mutant E. coli LT-A toxin
US8911742B2 (en) 1996-11-14 2014-12-16 The United States Of America As Represented By The Secretary Of The Army Transcutaneous immunization without heterologous adjuvant
US6036953A (en) * 1996-11-29 2000-03-14 The General Hospital Corporation Heterologous antigens in live cell V. cholerae strains
WO1998028005A1 (en) * 1996-12-24 1998-07-02 Smithkline Beecham Biologicals S.A. Chlamydia vaccines
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US7056521B2 (en) 1997-03-21 2006-06-06 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
WO1999047167A1 (en) * 1998-03-18 1999-09-23 The Administrators Of The Tulane Educational Fund Double mutant enterotoxin for use as an adjuvant
WO1999047165A1 (en) * 1998-03-18 1999-09-23 The Administrators Of The Tulane Educational Fund Production of purified mutant enterotoxin for use as an adjuvant
US6521745B1 (en) 1998-08-20 2003-02-18 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
US6693087B1 (en) 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
US7166289B2 (en) 1998-08-20 2007-01-23 Sanofi Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
GB2357507A (en) * 1998-09-07 2001-06-27 Univ Bristol Peptide fragments of cholera toxin B or enterotoxin B as vaccine adjuvants
WO2000014114A1 (en) * 1998-09-07 2000-03-16 University Of Bristol Peptide fragments of cholera toxin b or enterotoxin b as vaccine adjuvants
WO2000051634A1 (fr) * 1999-03-03 2000-09-08 The Kitasato Institute Preparations de vaccins contenant des acides gras comme composants
JP4551001B2 (ja) * 1999-03-03 2010-09-22 学校法人北里研究所 脂肪酸を構成成分とするワクチン製剤
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
EP1676586A1 (en) 1999-08-17 2006-07-05 GlaxoSmithKline Biologicals SA Method of separating rotavirus variants and live attenuated rotavirus vaccine
WO2001019998A1 (en) * 1999-09-15 2001-03-22 Mogam Biotechnology Research Institute Novel detoxified mutants of escherichia coli heat-labile enterotoxin
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
EP1964573A2 (en) 1999-10-22 2008-09-03 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
EP1792995A2 (en) 2000-05-08 2007-06-06 Sanofi Pasteur Limited Chlamydia secretory locus orf and uses thereof
EP1741782A2 (en) 2000-05-10 2007-01-10 Sanofi Pasteur Limited Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
US7364739B2 (en) 2000-08-25 2008-04-29 National Research Council Of Canada Haemophilus influenzae lipopolysaccharide inner-core oligosaccharide epitopes as vaccines for the prevention of Haemophilus influenzae infections
WO2002017961A1 (fr) * 2000-08-31 2002-03-07 The Kitasato Institute Preparation d'un vaccin renfermant un acide gras comme compose
US7560484B2 (en) 2000-08-31 2009-07-14 The Kitasato Institute Vaccine preparation containing fatty acid as a constituent
US7361355B2 (en) 2001-06-07 2008-04-22 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
US7285281B2 (en) 2001-06-07 2007-10-23 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
US7658931B2 (en) 2001-06-07 2010-02-09 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
WO2004020585A2 (en) * 2002-08-27 2004-03-11 Dow Agrosciences Llc Use of escherichia coli heat labile toxin as an adjuvant in birds and poultry
WO2004020585A3 (en) * 2002-08-27 2004-08-12 Dow Agrosciences Llc Use of escherichia coli heat labile toxin as an adjuvant in birds and poultry
EP2272532A2 (en) 2003-09-02 2011-01-12 GlaxoSmithKline Biologicals S.A. Rotavirus vaccine
EP2322211A1 (en) 2005-02-17 2011-05-18 GlaxoSmithKline Biologicals S.A. Live attenuated rotavirus vaccine for oral administration
EP2514824A2 (en) 2006-03-03 2012-10-24 Amorfix Life Sciences Ltd. Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
EP2495327A2 (en) 2006-03-03 2012-09-05 Amorfix Life Sciences Ltd. Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
EP2502999A2 (en) 2006-03-03 2012-09-26 Amorfix Life Sciences Ltd. Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
EP2514823A2 (en) 2006-03-03 2012-10-24 Amorfix Life Sciences Ltd. Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
WO2008143676A1 (en) 2007-05-23 2008-11-27 The Uab Research Foundation Detoxified pneumococcal neuraminidase and uses thereof
EP2674169A1 (en) 2007-09-11 2013-12-18 University Of Guelph Polysaccharide immunogens from Clostridium difficile
WO2010071986A1 (en) 2008-12-24 2010-07-01 Sanofi Pasteur Limited Modified steptococcus pneumonia pneumolysin (ply) polypeptides
WO2011003920A1 (en) 2009-07-08 2011-01-13 Abbott Biologicals B.V. Adjuvated influenza vaccine and use thereof
WO2012101509A2 (en) 2011-01-28 2012-08-02 Sanofi Pasteur Sa Immunological compositions against hiv
WO2013191225A1 (ja) 2012-06-20 2013-12-27 国立大学法人 東京大学 粘膜免疫賦活化剤及びｈｐｖ感染症治療用経口医薬組成物
WO2014140938A2 (en) 2013-03-14 2014-09-18 Centre Hospitalier Universitaire Vaudois Immunological methods
WO2017062246A1 (en) 2015-10-05 2017-04-13 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human rota virus g9p[6] strain and use as a vaccine
WO2017079833A1 (en) 2015-11-09 2017-05-18 The University Of British Columbia Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto
US10759837B2 (en) 2015-11-09 2020-09-01 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
US10772969B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
US10774120B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
US11905318B2 (en) 2015-11-09 2024-02-20 The University Of British Columbia Cyclic compound/peptide comprising an A-beta13-16 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-beta13-16 peptide
US11970522B2 (en) 2015-11-09 2024-04-30 The University Of British Columbia Cyclic compound/peptide comprising an A-beta15-18 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-BETA15-18 peptide
WO2018041891A1 (en) 2016-09-01 2018-03-08 Glaxosmithkline Biologicals Sa Compositions
US10751382B2 (en) 2016-11-09 2020-08-25 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
US11779629B2 (en) 2016-11-09 2023-10-10 The University Of British Columbia Compositions comprising cyclic peptides derived from an A-beta peptide
IT201900007060A1 (it) 2019-05-21 2020-11-21 St Superiore Di Sanita Cellule tumorali ingegnerizzate e loro usi
IT201900012540A1 (it) 2019-07-22 2021-01-22 Humanitas Mirasole Spa Inibitori di CHI3L1 e loro usi
WO2021013884A1 (en) 2019-07-22 2021-01-28 Humanitas Mirasole S.P.A. Inhibitors of chi3l1 and their uses

Also Published As

Publication number Publication date
HUT77869A (hu) 1998-09-28
DK0777490T3 (da) 2006-09-18
CZ56297A3 (en) 1997-10-15
NZ291262A (en) 1999-02-25
US6440423B1 (en) 2002-08-27
BR9508633A (pt) 1997-09-30
US6019982A (en) 2000-02-01
PL182667B1 (pl) 2002-02-28
ES2265148T3 (es) 2007-02-01
CN1182868C (zh) 2005-01-05
ZA956412B (en) 1996-03-11
EP0777490A1 (en) 1997-06-11
CA2198586A1 (en) 1996-03-07
FI120137B (fi) 2009-07-15
HU222985B1 (hu) 2004-01-28
CZ298131B6 (cs) 2007-07-04
NO970993L (no) 1997-04-25
DE69534992D1 (de) 2006-06-22
EP0777490A4 (en) 1998-11-18
RU2160606C2 (ru) 2000-12-20
PL318930A1 (en) 1997-07-21
ATE326231T1 (de) 2006-06-15
NO970993D0 (no) 1997-03-04
CA2198586C (en) 2010-10-12
JP3860208B2 (ja) 2006-12-20
AU3233795A (en) 1996-03-22
DE69534992T2 (de) 2007-05-10
NO317942B1 (no) 2005-01-10
PT777490E (pt) 2006-10-31
AU709779B2 (en) 1999-09-09
JPH10505059A (ja) 1998-05-19
FI970799A0 (fi) 1997-02-26
CN1164191A (zh) 1997-11-05
KR970705403A (ko) 1997-10-09
KR100399258B1 (ko) 2003-12-31
EP0777490B1 (en) 2006-05-17
MX9701445A (es) 1998-05-31
FI970799A (fi) 1997-04-24

Similar Documents

Publication Publication Date Title
AU709779B2 (en) Mutant enterotoxin effective as a non-toxic oral adjuvant
US6033673A (en) Double mutant enterotoxin for use as an adjuvant
US7485304B2 (en) Non-toxic mucosal adjuvant
US6436407B1 (en) Mutant enterotoxin effective as a non-toxic adjuvant
US20100255033A1 (en) Non-toxic double mutant forms of pertussis toxin as adjuvants
US6558678B1 (en) Preparation and use of formalin-killed colonization-factor-antigen (cfa)-expressing e. coli organisms for vaccination against enteric infection/diarrhea caused by enterotoxigenic e. coli bacteria in humans
US7063852B2 (en) Hybrid LT-A/CT-B holotoxin for use as an adjuvant
WO1999047164A1 (en) Use of mutant enterotoxin with excess b-subunit as an adjuvant
WO1998032461A1 (en) Mutant enterotoxin effective as a non-toxic adjuvant for hiv
Harada et al. Development of a mucosal complex vaccine against oral Salmonella infection in mice
MXPA97001445A (en) Effective mutating enterotoxin as adjuvant oral no tox
WO1999047165A1 (en) Production of purified mutant enterotoxin for use as an adjuvant

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 95195838.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU IS JP KG KP KR KZ LK LR LT LV MD MG MN MX NO NZ PL RO RU SG SI SK TJ TM TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PV1997-562

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2198586

Country of ref document: CA

Ref document number: 2198586

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1997/001445

Country of ref document: MX

Ref document number: 1019970701224

Country of ref document: KR

Ref document number: 970799

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: 1995928662

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 291262

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 1995928662

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019970701224

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV1997-562

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 1019970701224

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1995928662

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: PV1997-562

Country of ref document: CZ